Open AccessBudesonide (Jorveza)
Author(s) -
Reimbursement Reviews
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.174
Subject(s) - reimbursement , eosinophilic esophagitis , budesonide , medicine , family medicine , pathological , intensive care medicine , asthma , political science , disease , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses budesonide orodispersible tablets (Jorveza), 0.5 mg and 1 mg, oral.
Indication: Induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).